Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Relapsed and newly diagnosed Graves’ disease due to immunization against COVID-19: A case series and review of the literature

Hayri Bostan *, Bekir Ucan, Muhammed Kizilgul, Murat Calapkulu, Sema Hepsen, Umran Gul, Ilknur Ozturk Unsal, Erman Cakal

Department of Endocrinology and Metabolism, University of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey

ARTICLE INFO

Keywords:
Graves’ disease
Autoimmune thyroid diseases
Hyperthyroidism
SARS-CoV-2
Inactivated COVID-19 vaccine
mRNA vaccine

ABSTRACT

In addition to genetic factors, environmental factors such as viruses are thought to be triggers in the development of autoimmune thyroid diseases (AITD) such as Graves’ disease (GD). In this context, AITD cases that may be associated with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or immunization have begun to be reported in increasing numbers. Although it is not clear by which pathogenetic mechanisms immunization against coronavirus disease 2019 (COVID-19) triggers the development of AITD, both the potential effect of the adjuvants in the vaccines and the cross-reactivity that can be generated by the molecular similarity of viral particles with mammalian proteins seem to be possible mechanisms. In this article, 7 GD patients consisting of relapsed and newly diagnosed cases following the COVID-19 vaccination were presented. Of these 7 cases, 5 (71.4%) were female, and the median age of the patients was 47 years (range, 31–53). One of the patients was associated with the inactivated COVID-19 vaccine, while the others were associated with the mRNA COVID-19 vaccine. The median post-vaccination symptom onset was 7 days (range, 4–30). Three of the patients had a history of GD and one had a history of Hashimoto’s thyroiditis. Rapidly developing Graves’ ophthalmopathy was detected in one patient. These cases are cautionary that GD and its extrathyroidal manifestations may develop in a short period after COVID-19 vaccination. When considered together with the literature review, the history of AITD in approximately half of the patients suggests that more attention should be paid to these patients in the post-vaccination period. Nevertheless, multicenter, prospective studies are needed to better understand this possible causal relationship.

1. Introduction

Vaccines developed to control the coronavirus disease 2019 (COVID-19) pandemic, which has profoundly shaken the whole world, are promising in terms of ending this pandemic. However, side-effects that may be associated with increased vaccination at unprecedented levels have also begun to be carefully monitored by clinicians.

Although the factors that play a role in the development of Graves’ disease (GD) have not been fully elucidated, it is thought that genetic, epigenetic, and environmental factors may be the initiator [1]. In particular, the hypothesis that certain common viral infections (such as Epstein-Barr virus, influenza virus) trigger GD by causing epigenetic regulations in genes associated with GD susceptibility (such as thyroglobulin, thyrotropin receptor gene) is one of the potential mechanisms [1]. In addition, the molecular mimicry between the virus and various human antigens is thought to induce autoimmunity by causing cross-reactivity [2]. From this point of view, the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection-associated autoimmune thyroid diseases (AITD) can be expected. Indeed, some cases of GD and other AITD have been reported following SARS-CoV-2 infection and its immunization [3–13]. When considering the pre-COVID-19 period, in a case report published after the H1N1 pandemic, two newly-diagnosed autoimmune diseases (GD and narcolepsy type 1) had been detected following H1N1 vaccination in a 40-year-old female patient [14].

In this paper, 7 COVID-19 vaccine-associated GD cases are presented and the literature is reviewed. In addition, to the best of our knowledge, the current study describes the first case of inactivated COVID-19 vaccine-associated GD in the literature.

* Corresponding author. Department of Endocrinology and Metabolism, Diskapi Yildirim Beyazit Training and Research Hospital, Ziraat Mahallesi, Şt. Ömer Halidemir Blvd No:1, 06110, , Ankara, Turkey.
E-mail address: Hayri.Bostan@saglik.gov.tr (H. Bostan).

https://doi.org/10.1016/j.jaut.2022.102809
Received 2 January 2022; Received in revised form 14 February 2022; Accepted 19 February 2022
Available online 24 February 2022
0896-8411/© 2022 Elsevier Ltd. All rights reserved.
2. Methods

The literature search was conducted in order to identify COVID-19 vaccine-related GD case reports or series published until the end of December 2021 from the PubMed online database, using the following search string: (“Graves’ OR “thyroiditis” OR “thyrotoxicosis”) AND (“COVID-19” OR “SARS-CoV-2”) AND (“vaccine” OR “immunization”).

The descriptive analysis was conducted using SPSS software (version 23.0, SPSS, IBM Corporation, NY, USA). Categorical data were expressed as frequencies and percentages (%). The median (range) was calculated for continuous variables.

3. Results

3.1. Relapsed Graves’ disease

3.1.1. Patient 1

A 44-year-old female patient was diagnosed with GD 13 years ago and received treatment for 1 year. She was followed in remission after discontinuation of antithyroid treatment. There has been no follow up for the last 1.5 years due to the pandemic and the patient has not had a documented SARS-CoV-2 infection. One week after receiving the first dose of inactivated COVID-19 vaccine (CoronaVac®) on June 10, 2021, complaints of excessive sweating, palpitation, and fatigue started. After a 2-month delayed admission, the physical examination revealed an enlarged thyroid gland with palpation. Thyroid hormone and antibody panel results showed thyroid-stimulating hormone (TSH) < 0.01 mIU/L (0.27–4.2), free thyroxine (fT4):2.67 ng/dL (0.93–1.7), free triiodothyronine (fT3): 9.65 ng/L (2–4.4), anti-thyroid peroxidase (anti-TPO):284 IU/ml (0–34), anti-thyroglobuline (anti-Tg):119 IU/ml (0–115), and TSH receptor antibody (TRAb):12.18 IU/L (<1.5). Thyroid ultrasonography (US) showed hypoechoic areas separated by fibrous septa and increased parenchymal vascularity in a ‘Thyroid inferno’ pattern with Doppler (Fig. 1 A). With the diagnosis of relapsed GD, treatment with 20 mg/day methimazole (MMI) and propranolol was initiated.

3.1.2. Patient 2

A 49-year-old male patient who was diagnosed with GD in December 2018 is being followed up routinely in our outpatient clinic. After 18 months of antithyroid treatment, TRAb became negative and the treatment was discontinued. The patient, who was asymptomatic in the last 2 years due to the pandemic and the patient has not had a documented SARS-CoV-2 infection. The patient, who had the first dose of mRNA COVID-19 vaccine (Pfizer-BioNTech®) at the beginning of August 2021, presented at our clinic with complaints of hot flushes, weakness, and sweating that had started approximately 3 weeks after the vaccination. Thyroid hormone and antibody panel results were TSH<0.01 mIU/L (0.27–4.2), fT4:7.77 ng/dL (0.93–1.7), fT3: 21.70 ng/L (2–4.4), anti-TPO:325 IU/ml (0–34), anti-Tg:11 IU/ml (0–115), and TRAb:19.30 IU/L (<1.5). A moderate increase in parenchymal vascularity of the thyroid gland was observed with Doppler US. With the diagnosis of relapsed GD, 20 mg/day MMI and propranolol were started. After 5 weeks, the fT4 level decreased to 1.43 ng/dL and fT3 decreased to 6.19 ng/L.

3.2. Conversion from Hashimoto’s thyroiditis to Graves’ disease

3.2.1. Patient 4

A 53-year-old female patient who was diagnosed with Hashimoto’s thyroiditis in September 2019 has been followed up with levothyroxine (LT) replacement for 2 years. The patient, who had her last visit before vaccination in April 2021, was found to be euthyroid with 50 mcg/day LT. She was infected with SARS-CoV-2 in August 2020. The patient, who received the first dose of mRNA COVID-19 vaccine (Pfizer-BioNTech®) in the middle of June 2021, and the second dose 1 month later, started to complain of palpitations, sweating, and weight loss 1 week after the first dose of vaccination. While continuing the LT treatment during this period, the patient presented again at our outpatient clinic in October 2021. The thyroid hormone panel results were TSH<0.01 mIU/L (0.27–4.2), fT4: 4.01 ng/dL (0.93–1.7), fT3: 8.83 ng/L (2–4.4). When LT

Fig. 1. (A) Patient 1: Doppler ultrasonography image of the left thyroid lobe consistent with the ‘Thyroid inferno’ pattern on the transverse axis, (B) Patient 4: scintigraphy image showing bilateral diffuse increased technetium pertechnetate uptake with suppressing background activity in the thyroid gland in anterior pinhole view.
replacement was stopped and re-evaluated 12 days later, fT4: 2.95 ng/dL, fT3: 9.05 ng/L, Tg: 1.32 ng/mL (3.68–64.15), anti-TPO: 55 IU/ml (0–34), anti-Tg: 1197 IU/ml (0–115) and TRAb: 17.84 IU/L (<1.5) were detected. US revealed normal thyroid gland sizes and highly heterogeneous parenchyma, and a minimal increase in vascularity was detected in the parenchyma with Doppler. Subsequently, increased diffuse activity uptake in both thyroid lobes was observed on thyroid scintigraphy (Fig. 1B), and GD was diagnosed. Treatment was started of propranolol and 15 mg/day MMI. Two months later, the fT4 level decreased to 0.9 ng/dL and fT3 decreased to 2.37 ng/L, and the MMI dose was reduced to 10 mg/day.

3.3. Rapidly developing Graves’ ophthalmopathy

3.3.1. Patient 5

A 51-year-old female patient with no known history of thyroid disease and living in an iodine-deficient area was referred to our outpatient clinic in August 2021 due to the detection of hyperthyroidism and exophthalmos. The patient, who had diabetes and hypertension under control with medication, had impaired blood pressure control for the last 6 weeks, and complaints of palpitations, sweating, and fever. She had received the first dose of mRNA COVID-19 vaccine (Pfizer-BioNTech®) in early June 2021 and the second dose 1 month later. Complaints of proptosis, irritation, and dryness, especially in the right eye, started 4 days after the second dose and gradually increased. The patient stated that her eyes were completely normal in the period before the vaccine. On physical examination, the thyroid gland was palpated as nodular enlargement and there was mild-to-moderate active Graves’ ophthalmopathy (GO) with a clinical activity score (CAS) of 3 in the right eye (Fig. 2A). Thyroid hormone and antibody panel results were TSH<0.01 mIU/L (0.27–4.2), fT4: 3.72 ng/dL (0.93–1.7), fT3: 12.6 ng/L (2–4.4), anti-TPO: 12.4 IU/ml (0–34), anti-Tg: 18.2 IU/ml (0–115), and TRAb: 5.04 IU/L (<1.5). On US examination, the size of the thyroid gland was greatly enlarged and there was a multinodular goiter, the largest of which was a 22 mm iso-hypoechoic nodule on the longitudinal axis in the left lower lobe. Thyroid scintigraphy showed a hypoaemic multinodular hyperplasic thyroid gland in the background of hyperthyroidism (Fig. 2B). With the diagnosis of GD, 15 mg/day MMI and propranolol were started. In the 4-month follow-up, despite the hyperthyroidism being under control, the decision was made for total thyroidecomy by the multidisciplinary council in December 2021 for the patient who had progressive ocular findings, increased TRAb levels, multinodular goiter, and was willing to have surgery. Histopathological examination revealed a 12 mm classic type papillary thyroid carcinoma focus in the nodule in the left lobe, while the right lobe and isthmus were consistent with nodular hyperplasia and lymphocytic thyroiditis. After thyroidecomy, her ocular findings showed a significant regression.

3.4. Newly diagnosed Graves’ disease

3.4.1. Patient 6

A 47-year-old female patient with no known history of thyroid disease was referred to our clinic after hyperthyroidism was detected prior to the cholecystectomy surgery. The patient was found to be euthyroid in routine control examinations in 2020. The patient had not had SARS-CoV-2 infection, and complaints of sweating and palpitations had been ongoing for 3 months. She had received the first dose of mRNA COVID-19 vaccine (Pfizer-BioNTech®) at the beginning of June 2021 and the second dose 1 month later, and the current complaints had started 5 days after the first dose of vaccination. It was revealed that her complaints continued without aggravation after the second dose of vaccination. Thyroid hormone and antibody panel results were TSH<0.01 mIU/L, fT4: 3.32 ng/dL, fT3: 11.0 ng/L, anti-TPO:11.2 IU/ml (0–34), anti-Tg: 320 IU/ml (0–115), and TRAb: 22.74 IU/L (<1.5). In addition, when laboratory tests were evaluated retrospectively, it was observed that the patient had overt hyperthyroidism 20 days after the first dose of the vaccine. On US examination, diffuse millimetric hypoechoic areas in the bilaterally enlarged thyroid gland and moderate vascularity increase in the parenchyma with Doppler were observed. With the diagnosis of GD, treatment was started of MMI 15 mg/day and propranolol. One month later, the fT4 level decreased to 1.72 ng/dL and fT3 decreased to 4.18 ng/L.

3.4.2. Patient 7

A healthy, 46-year-old male patient with no known history of thyroid disease presented with symptoms of hyperthyroidism at the beginning of October 2021. The patient had not had any recent laboratory examination, and did not have a documented SARS-CoV-2 infection. He had complaints of emotional lability, sweating, palpitations, and weight loss ongoing for 2 months. The patient had received the second dose of mRNA COVID-19 vaccine (Pfizer-BioNTech®) one month after the first dose in mid-July 2021 and the current complaints started approximately 3 weeks after the second dose of vaccination. Thyroid hormone and antibody panel results were TSH<0.01 mIU/L (0.27–4.2), fT4>7.77 ng/dL (0.93–1.7), fT3: 25.30 ng/L (2–4.4), anti-TPO: 146 IU/ml (0–34), anti-Tg: 334 IU/ml (0–115) and TRAb: 9.10 IU/L (<1.5). US showed diffuse millimetric hypoechoic areas in the bilaterally enlarged thyroid gland and increased parenchymal vascularity in a ‘Thyroid inferno’ pattern with Doppler. In addition, an isoechoic thyroid nodule with a diameter of 34 mm in the longitudinal axis was detected. MMI 20 mg/day and propranolol were started with the diagnosis of GD in the patient whose present nodule was hypoaemic on thyroid scintigraphy. One month later, the fT4 level decreased to 1.97 ng/dL and fT3 decreased to 6.76 ng/L and the MMI dose was increased to 25 mg/day.

Fig. 2. (A) Patient 5: severe proptosis, eyelid retraction, mild peribullar edema, and 1+ chemosis seen in the right eye two months after the second dose of vaccine, (B) scintigraphy image of the same patient with bilaterally increased technetium pertechnetate uptake in the thyroid gland and decreased activity uptake in the left thyroid lower lobe in anterior pinhole view.
3.5. Literature review

The COVID-19 vaccine-associated GD cases published until the end of December 2021 and the current cases were summarized in Table 1. It was identified that 13 GD cases associated with the COVID-19 vaccine have been reported [4-13]. Eight (61.5%) of these cases were women, and the median age at diagnosis was 40 (range, 28–71) years. Five of the reported cases had a previous history ofAITD [4-8]. Nine patients were associated with the mRNA COVID-19 vaccine, while the remaining 4 were associated with the vectored COVID-19 vaccine. The median post-vaccination symptom onset was 10 (range, 2–38) days.

4. Discussion

In this paper, 7 GD patients consisting of relapsed and newly diagnosed cases following the COVID-19 vaccination were presented with four different onset histories. Five of the current patients (71.4%) were female and the median age of the patients was 47 years (range, 31–53). In the current study, the first case of GD associated with an inactivated COVID-19 vaccine was presented, while other cases were associated with the mRNA COVID-19 vaccine. The median post-vaccination symptom onset was 7 days (range, 4–30). Considered together with the review of literature, it seems that COVID-19 vaccine-associated GD cases are similar to classical GD cases in terms of age and gender, and symptoms begin approximately 7–10 days after vaccination (Table 1). It was noteworthy that approximately half of the patients had a previous history ofAITD (4 patients in the current presentation, 5 patients in the literature) (Table 1) [4-8]. In addition, as in cases of classical GD, the majority of patients with vaccine-associated GD had increased titers of anti-TPO and anti-Tg titers, as well as TRAb [15].

During the pandemic, it has been well observed that SARS-CoV-2 causes damage to many tissues and organs by causing a hyperactive immune response in the individual. This is also true for thyroid follicular cells that express the ACE-2 receptor that SARS-CoV-2 uses to enter the cells [16]. There are reports in the literature of cases of GD, Hashimoto’s thyroiditis, and subacute thyroiditis developing in the post-COVID-19 period [3]. Likewise, some autoimmune/inflammatory thyroiditis cases thought to be associated with immunization against COVID-19 are still being reported, with the first GD cases reported in May 2021 [13]. It has been argued that the potential cause may be inappropriate reactivity triggered by the adjuvants used to increase the immunogenicity of the vaccine [13,17]. This phenomenon, also known as autoimmune/inflammatory syndrome induced by adjuvants (ASIA), was first described by Shoenfeld and Agmon-Levin in 2011 [18]. In the present study, the inactivated COVID-19 vaccine, which is shown in this paper for the first time to be associated with GD, also contains aluminum hydroxide as an adjuvant, and this adjuvant may have contributed to the formation of the hyperimmune response in the thyroid gland by activating various immune cascades. Three-quarters of the cases identified to date have been associated with the COVID-19 mRNA vaccine, which contains no known adjuvants. However, recently, Alameh et al. demonstrated that the nucleoside-modified mRNA encapsulated in lipid nanoparticles (mRNA-LNPs) included in the Pfizer-BioNTech® COVID-19 vaccine strongly affected the T follicular helper cell and humoral responses, leading to immunostimulation [19]. This suggests that mRNA-LNPs may themselves act as an adjuvant and lead to ASIA syndrome. On the other hand, Vojdani et al. determined that SARS-CoV-2 proteins (spike protein, membrane protein, and nucleoprotein) have a significant number of amino acid sequence similarities with TPO proteins ranging from 50 to 70% [20]. In addition, Kanduc and Shoenfeld also demonstrated that the SARS-CoV-2 spike proteins are molecularly similar mainly to human, mouse, and rat hexa/heptapeptides, at a much higher rate compared to other coronavirus family members [21]. In the light of these studies, both the cross-reactivity resulting from the molecular mimicry of SARS-CoV-2 spike proteins with TSH receptor antigens and/or other thyroid proteins, and the evidence that LNPs act as adjuvants and stimulate a robust immune response suggest that multiple mechanisms may be involved in the occurrence of GD cases following the COVID-19 mRNA vaccination.

In the current study, three patients had relapsed GD after vaccination. Relapse develops in approximately 50% of patients in GD, and recent reviews have shown that two-thirds of these relapses occur 6–18 months after stopping antithyroid treatment [22]. According to 2016 American Thyroid Association guidelines, patients who are still euthyroid 12 months after drug discontinuation are considered in remission [23]. While relapse after years in patient 1 suggests the possible causal relationship, relapse of the disease one year after drug discontinuation in patients 2 and 3 can also be considered as a natural course of GD. However, the fact that both cases, which were known to be euthyroid shortly before the vaccine, became symptomatic in the post-vaccine period, make it necessary to question a possible interaction. In addition, cases in the literature of GD that relapsed after COVID-19 vaccine, two after 11 years and one after 17 years, strengthen the possible relation [5,6,8]. Moreover, in a case with active GD [4], the increase in the antithyroid dose requirement after COVID-19 vaccination also indicates that vaccination may aggravate the pre-existing autoimmune disease. Although the factors causing relapse are still not clearly known, the current cases warn that vaccination may be a trigger factor for GD relapse.

Conversion from Hashimoto’s thyroiditis to GD has been reported with limited case series [24]. In these patients, some factors affecting the immune response (e.g. drug replacement therapy, pregnancy) are thought to trigger the conversion of thyroid blocking antibodies to stimulating antibodies [25]. In addition to the case reported in this paper, Lui et al. also described a case with a history of hypothyroidism who developed COVID-19 mRNA vaccine-associated GD [7]. Although not addressed to date, the current cases demonstrate that vaccination may induce antibody conversion in hypothyroid individuals receiving LT replacement.

Although half of GD patients have ocular symptoms, 3–5% of GD patients develop severe GO [26]. Ocular symptoms often appear with the onset of hyperthyroidism or within 18 months [26]. Interestingly, in patient 5, we were faced with simultaneously developing GD and unilateral GO and coincidental papillary thyroid carcinoma after the COVID-19 mRNA vaccination. This patient, who was living in an iodine-deficient area, had a previously undetected multinodular goiter. Recently, Rubinstein et al. described a thyroid eye disease that developed rapidly after the COVID-19 mRNA vaccine and was controlled with teprotumumab in a patient diagnosed with GD 11 years previously and who was being followed up in remission [8]. These cases suggest that GO as well as GD may develop more rapidly than normal in the hyperimmune environment created after the COVID-19 immunization.

In conclusion, vaccines carrying inactivated particles or mRNA of SARS-CoV-2 may make the thyroid gland a potential target by the aforementioned hypothetical mechanisms. The fact that most cases of vaccine-associated GD have been reported after mRNA vaccination highlights the possibility of immune cross-reactivity as well as the adjuvant effects of LNPs. In patients with a previous history ofAITD (especially GDs in remission), where an autoimmune response can be triggered more easily, attention should be paid to relapse in the post-vaccination period. With these few reported cases, it would not be correct to make definitive judgments about the relationship between the COVID-19 vaccine and GD, and the vaccination program must be followed in order to control the pandemic. In this regard, multicenter, prospective studies are needed to explain the causal relationship and better elucidate the pathogenetic mechanisms.

Disclosure

No financial grant has been received for the current study. Written informed consent was obtained from all patients for publication of this
| Author reference | Age/ Sex | Disease history | Presence of COVID-19 history | COVID-19 vaccine name -dose | Pre-vaccination thyroid hormone status* | Post-vaccination symptom onset (days) | Laboratory test results at diagnosis | Antithyroid treatment |
|------------------|---------|-----------------|----------------------------|-----------------------------|--------------------------------------|------------------------------------|---------------------------------|----------------------|
| **Reported cases of Graves’ Disease after COVID-19 vaccination.** |
| **Relapsed Graves’ Disease** | Current patient 1 | 44/F | GD in remission (for 12 years) | No | CoronaVac® - 1st | N/A | 7 | TSH (RR) fT4 (RR) fT3 (RR) Anti-TPO Anti-Tg TRAb | Candidate for treatment with MMI 20 mg/day |
| | Current patient 2 | 49/M | GD in remission (for 1 year) | No | Pfizer-BioNTech® - 2nd | Euthyroid without treatment | 30 | -0.01 mIU/L (0.27-4.2) 3.86 ng/dL (0.93-1.7) 21.7 ng/mL (2.4-4.4) | + + 19.3 IU/L (1.5) |
| | Current patient 3 | 31/F | GD in remission (for 1 year) | No | Pfizer-BioNTech® - 1st | Euthyroid without treatment | 21 | -0.01 mIU/L (0.27-4.2) >7.77 ng/dL (0.93-1.7) 21.7 ng/mL (2.4-4.4) | + - 19.3 IU/L (1.5) |
| [4] | 30/F | Active GD (for 3 years) | N/A | ChAdOx1 nCoV19 (Oxford-AstraZeneca) - 1st | Euthyroid with MMI 2.5 mg/day | 4 | TSH (RR) fT4 (RR) fT3 (RR) Anti-TPO Anti-Tg TRAb | Patient 2: Current MMI 20 mg/day |
| [5] | 34/F | GD in remission (for 11 years) | N/A | Pfizer-BioNTech® - 1st | Euthyroid without treatment | 10 | -0.01 mIU/L (0.4-2.75) 2.54 ng/dL (0.75-1.6) 21.1 ng/mL (2.4-4.4) | N/A N/A 13.4 IU/L (0.175) |
| [6] | 71/F | GD in remission (for 17 years) | N/A | Pfizer-BioNTech® - 2nd | Euthyroid without treatment | 35 | TSH (RR) fT4 (RR) fT3 (RR) Anti-TPO Anti-Tg TRAb | Patient 3: Current MMI 20 mg/day |
| **Conversion from Hashimoto’s thyroiditis to Graves’ disease** | Current patient 4 | 53/F | Hashimoto’s thyroiditis (for 2 years) | Yes | Pfizer-BioNTech® - 2nd | Euthyroid with LT replacement | 7 | -0.01 mIU/L (0.27-4.2) 4.01 ng/dL (0.93-1.7) 8.83 ng/mL (2.4-4.4) | + + 17.8 IU/L (1.5) |
| [7] | 40/F | Hashimoto’s thyroiditis (for 8 years) | No | Pfizer-BioNTech® - 2nd | Euthyroid with LT replacement | -30 | TSH (RR) fT4 (RR) fT3 (RR) Anti-TPO Anti-Tg TRAb | Patient 4: Current MMI 15 mg/day |
| **Rapidly developing Graves’ ophthalmopathy** | Current patient 5 | 51/F | DM, HT | No | Pfizer-BioNTech® - 2nd | Euthyroid | 4 | -0.01 mIU/L (0.27-4.2) 3.72 ng/dL (0.93-1.7) 12.6 ng/mL (2.4-4.4) | – – 5.04 IU/L (1.5) |
| [8] | 50/F | GD in remission (for 11 years) | N/A | Pfizer-BioNTech® - 2nd | Euthyroid with LT replacement | 3 | TSH (RR) fT4 (RR) fT3 (RR) Anti-TPO Anti-Tg TRAb | Patient 5: Current MMI 15 mg/day |
| **Newly diagnosed Graves’ Disease** | Current patient 6 | 47/F | Obesity | No | Pfizer-BioNTech® - 1st | Euthyroid | 5 | -0.01 mIU/L (0.27-4.2) 3.32 ng/dL (0.93-1.7) 11.0 ng/mL (2.4-4.4) | – + 22.7 IU/L (1.5) |
| | Current patient 7 | 46/M | – | No | Pfizer-BioNTech® - 2nd | Euthyroid | 21 | -0.01 mIU/L (0.27-4.2) >7.77 ng/dL (0.93-1.7) 21.7 ng/mL (2.4-4.4) | + + 9.1 IU/L (1.5) |
| [6] | 46/M | – | N/A | Pfizer-BioNTech® - 1st | Euthyroid | 15 | TSH (RR) fT4 (RR) fT3 (RR) Anti-TPO Anti-Tg TRAb | Patient 7: Current MMI 15 mg/day |
| [9] | 32/M | – | N/A | Vaxzevria® (Oxford-AstraZeneca) - 2nd | Euthyroid | 10 | TSH (RR) fT4 (RR) fT3 (RR) Anti-TPO Anti-Tg TRAb | Patient 8: Current MMI 15 mg/day |
| [9] | 35/M | – | N/A | Vaxzevria® (Oxford-AstraZeneca) - 1st | Euthyroid | 5 | TSH (RR) fT4 (RR) fT3 (RR) Anti-TPO Anti-Tg TRAb | Patient 9: Current MMI 15 mg/day |
| [10] | 52/M | Vitiligo, DM | No | Pfizer-BioNTech® - 2nd | Euthyroid | 30 | TSH (RR) fT4 (RR) fT3 (RR) Anti-TPO Anti-Tg TRAb | Patient 10: Current MMI 15 mg/day |
| [11] | 38/F | – | N/A | Pfizer-BioNTech® - 1st | Euthyroid | 12 | TSH (RR) fT4 (RR) fT3 (RR) Anti-TPO Anti-Tg TRAb | Patient 11: Current MMI 15 mg/day |
| [12] | 70/M | N/A | No | ChAdOx1 nCoV19 (Oxford-AstraZeneca) - 2nd | Euthyroid | 2 | TSH (RR) fT4 (RR) fT3 (RR) Anti-TPO Anti-Tg TRAb | Patient 12: Current MMI 15 mg/day |
| [13] | 40/F | HT | Yes | Pfizer-BioNTech® - 1st | Euthyroid | 2 | TSH (RR) fT4 (RR) fT3 (RR) Anti-TPO Anti-Tg TRAb | Patient 13: Current MMI 15 mg/day |
| [13] | 28/F | – | No | Pfizer-BioNTech® - 2nd | Euthyroid | 3 | TSH (RR) fT4 (RR) fT3 (RR) Anti-TPO Anti-Tg TRAb | Patient 14: Current MMI 15 mg/day |

COVID-19: Coronavirus disease-2019; GD: Graves’ disease; DM: Diabetes Mellitus; HT: Hypertension; TSH: thyroid-stimulating hormone; fT4: free thyroxine; fT3: free triiodothyronine; Anti-TPO: anti-thyroid peroxidase; Anti-Tg: anti-thyroglobulin; TRAb: TSH receptor antibody; MMI: methimazole; CMZ: carbimazole; LT: levothyroxine; N/A: not available.

* Indicates the thyroid hormone status in the period 6 months before vaccination.
study and accompanying images.

**Author statements**

Hayr Bozun: Conceptualization, Investigation, Data curation, Writing – original draft. Bekir Ucan: Conceptualization, Investigation, Writing – original draft. Muhammed Kizilgul: Writing – review & editing, Supervision. Murat Calapkulu: Investigation, Data curation. Sema Hepsen: Writing – review & editing. Umran Gul: Data curation. Ilknur Ozturk Unsal: Writing – review & editing. Erman Calak: Writing – review & editing, Supervision.

**Declaration of competing interest**

The authors have no conflicts of interest to disclose.

**References**

[1] T.F. Davies, S. Andersen, R. Latif, Y. Nagayama, G. Barbesino, M. Brito, et al., Graves’ disease, Nat. Rev. Dis. Prim. 6 (2020) S2. https://doi:10.1038/s41572-020-0184-y.

[2] M.B.A. Oldstone, Molecular mimicry: its evolution from concept to mechanism as a cause of autoimmune diseases, Monoclon. Antibodies Immunodiagn. Immunother. 33 (2014) 158–165. https://doi:10.1089/mbi.2013.0090.

[3] A.K. Murugan, A.S. Alzahrani, SARS-CoV-2: emerging role in the pathogenesis of various thyroid diseases, J. Inflamm. Res. 14 (2021) 6191–6221. https://doi:10.2147/JIR.S327955.

[4] C. Sriphrapradang, Aggravation of hyperthyroidism after heterologous prime-boost immunization with inactivated and adenovirus-vectored SARS-CoV-2 vaccine in a patient with Graves’ disease, Endocrine 74 (2021) 226–227. https://doi:10.1007/s12020-021-02879-8.

[5] G. Pierman, E. Delgrange, C. Jonas, Recurrence of Graves’ disease (a TH1-type cytokine disease) following SARS-CoV-2 mRNA vaccine administration: a simple coincidence? Eur. J. Case Rep. Intern. Med. 8 (2021), 002807. https://doi:10.12986/2021_002807.

[6] G. Zettinig, M. Krebs, Two further cases of Graves’ disease following SARS-CoV-2 vaccination, J. Endocrinol. Invest. (2021). https://doi:10.1007/s40618-021-0184-y.

[7] D.T.W. Lui, K.K. Lee, C.H. Lee, A.C.H. Lee, I.F.N. Hung, K.C.B. Tan, Development of Graves’ disease after SARS-CoV-2 mRNA vaccination: a case report and literature review, Front. Public Health 9 (2021) 779964. https://doi:10.3389/fpubh.2021.779964.

[8] T.J. Rubinstein, Thyroid eye disease following COVID-19 vaccine in a patient with a history Graves’ disease: a case report, Ophthalmic Plast. Reconstr. Surg. 37 (2021) e221–e223. https://doi:10.1097/OPX.0000000000002059.

[9] L. di Filippo, L. Castellino, A. Giustina, Occurrence and response to treatment of Graves’ disease after COVID vaccination in two male patients, Endocrine (2021). https://doi:10.1007/s12020-021-02919-3.

[10] A. Patriarca, S.M. Ferrari, A. Antonelli, P. Fallahi, A case of Graves’ disease and type 1 diabetes mellitus following SARS-CoV-2 vaccination, J. Autoimmun. 125 (2021) 102738. https://doi:10.1016/j.jaut.2021.102738.

[11] A. Pujol, L.-A. Gómez, C. Gallegos, J. Nicolaou, P. Sanchis, M. González-Freire, et al., Thyroid as a target of adjuvant autoimmunity/inflammatory syndrome due to mRNA-based SARS-CoV-2 vaccination: from Graves’ disease to silent thyroiditis, J. Endocrinol. Invest. (2021). https://doi:10.1007/s40618-021-01707-0.

[12] C. Sriprapradang, P. Ch Shantavasinluk, Graves’ disease following SARS-CoV-2 vaccination, Endocrine 74 (2021) 473–474. https://doi:10.1007/s12020-021-02902-y.

[13] O. Vera-Lastra, A.O. Navarro, M.P.C. Domínguez, G. Medina, T.S. Valadez, L. J. Jara, Two cases of Graves’ disease following SARS-CoV-2 vaccination: an autoimmune/inflammatory syndrome induced by adjuvants, Thyroid 31 (2021) 1430–1439. https://doi:10.1089/thy.2021.0142.

[14] S. Leiva, J. Madrazo, C. Poleda, Narcology with cataplexy and hyperthyroidism suddenly appeared after H1N1 vaccination, Sleep Sci 11 (2018) 34–36. https://doi:10.9593/1984-0063.20180008.

[15] E. Frohlich, R. Wahl, Thyroid autoimmunity: role of anti-thyroid antibodies in thyroid and extra-thyroidal diseases, Front. Immunol. 8 (2017) 521. https://doi:10.3389/fimmu.2017.00521.

[16] E. Lazartigues, M.M.F. Qadir, F. Mauvais-Jarvis, Endocrine significance of SARS-CoV-2’s reliance on ACE2, Endocrinology 161 (2020), bqua108. https://doi:10.1210/endo/bqua108.

[17] N.L. Bragazzi, A. Hely, A. Watad, M. Adawi, H. Amital, Y. Shoenfeld, ASIA syndrome and endocrine autoimmune disorders, Best Pract. Res. Clin. Endocrinol. Metabol. 34 (2020) 101412. https://doi:10.1016/j.jbend.2020.101412.

[18] Y. Shoenfeld, N. Aymon-Levin, ‘ASIA’—autoimmunity/inflammatory syndrome induced by adjuvants, J. Autoimmun. 36 (2011) 4–8. https://doi:10.1016/j.jaut.2010.07.003.

[19] M.-G. Alaméh, I. Tombaca, E. Bettini, K. Lederer, C. Sittplangkoon, J.R. Wilmore, et al., Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses, Immunity 54 (2021) 2877–2892, e1–e7. https://doi:10.1016/j.immuni.2021.11.001.

[20] A. Vojdani, E. Vojdani, D. Khazzarine, Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: implications for autoimmune diseases, Front. Immunol. 11 (2021) 617089. https://doi:10.3389/fimmu.2020.617089.

[21] D. Kanduc, Y. Shoenfeld, Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: implications for the vaccine, Immunol. Metabol. 34 (2020) 101412. https://doi:10.1016/j.immuni.2020.101452.

[22] T. Straja, H. Fehlberg, A. Kurtz, L. Gaebelin, C. Degen, B. Mueller, et al., Can we predict relapse in Graves’ disease? Results from a systematic review and meta-analysis, Eur. J. Endocrinol. 176 (2017) 87–97. https://doi:10.1530/EJE-16-0725.

[23] D.S. Ross, H.B. Burch, D.S. Cooper, M.C. Greenelee, P. Laurberg, A.L. Maia, et al., American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis, Thyroid 26 (2016) 1343–1421. https://doi:10.1089/thy.2016.0142.

[24] B. Gonzalez-Aguilar, D. Beteta, L. Lutteri, E. Cavalier, V. Geenen, A. Beckers, et al., Conversion to Graves disease from Hashimoto thyroiditis: a study of 24 patients, Arch. Endocrinol. Metab. 62 (2018) 609–614. https://doi:10.20945/2359-3997.0000086.

[25] S.M. McLachlan, B. Rapoport, Thyrotropin-blocking autoantibodies and thyroid-stimulating autoantibodies: potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa, Thyroid 23 (2013) 14–24. https://doi:10.1089/thy.2012.0374.

[26] R.S. Bahn, Graves’ ophthalmopathy, N. Engl. J. Med. 362 (2010) 726–738. https://doi:10.1056/NEJMra0900570.